全文获取类型
收费全文 | 56348篇 |
免费 | 6144篇 |
国内免费 | 1768篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 1145篇 |
妇产科学 | 441篇 |
基础医学 | 5433篇 |
口腔科学 | 70篇 |
临床医学 | 4948篇 |
内科学 | 8511篇 |
皮肤病学 | 147篇 |
神经病学 | 204篇 |
特种医学 | 2285篇 |
外国民族医学 | 105篇 |
外科学 | 4800篇 |
综合类 | 10613篇 |
预防医学 | 2046篇 |
眼科学 | 64篇 |
药学 | 4708篇 |
63篇 | |
中国医学 | 2618篇 |
肿瘤学 | 16000篇 |
出版年
2024年 | 34篇 |
2023年 | 1067篇 |
2022年 | 1549篇 |
2021年 | 2629篇 |
2020年 | 2914篇 |
2019年 | 2933篇 |
2018年 | 1911篇 |
2017年 | 2370篇 |
2016年 | 2580篇 |
2015年 | 2597篇 |
2014年 | 3951篇 |
2013年 | 3770篇 |
2012年 | 3475篇 |
2011年 | 3726篇 |
2010年 | 2907篇 |
2009年 | 2732篇 |
2008年 | 2683篇 |
2007年 | 2990篇 |
2006年 | 2619篇 |
2005年 | 2348篇 |
2004年 | 1860篇 |
2003年 | 1554篇 |
2002年 | 1280篇 |
2001年 | 1133篇 |
2000年 | 919篇 |
1999年 | 662篇 |
1998年 | 562篇 |
1997年 | 531篇 |
1996年 | 451篇 |
1995年 | 427篇 |
1994年 | 431篇 |
1993年 | 321篇 |
1992年 | 342篇 |
1991年 | 296篇 |
1990年 | 243篇 |
1989年 | 209篇 |
1988年 | 207篇 |
1987年 | 170篇 |
1986年 | 148篇 |
1985年 | 126篇 |
1984年 | 102篇 |
1983年 | 90篇 |
1982年 | 80篇 |
1981年 | 72篇 |
1980年 | 80篇 |
1979年 | 54篇 |
1978年 | 35篇 |
1977年 | 30篇 |
1976年 | 15篇 |
1975年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Adam H. Fox MD MS Mizuki Nishino MD Raymond U. Osarogiagbon MBBS M. Patricia Rivera MD Lauren S. Rosenthal MPH Robert A. Smith PhD Farhood Farjah MD Lynette M. Sholl MD Gerard A. Silvestri MD MS Bruce E. Johnson MD 《CA: a cancer journal for clinicians》2023,73(4):358-375
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios. 相似文献
2.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
3.
4.
5.
Biniam Kidane MD MSc Ian J. Gerard MD PhD Jonathan Spicer MD PhD Julian O. Kim MD MSc BEng Pierre O. Fiset MD PhD Paul Wawryko MD Matthew J. Cecchini MD PhD Richard Inculet MD Bassam Abdulkarim MD PhD Dalilah Fortin MD Mehdi Qiabi MD MSc Gefei Qing MD Stephanie Enns BSc Bashir Bashir MBBS James Tankel MD Elliot Wakeam MD Andrew Warner MSc Neil Kopek MD Brian P. Yaremko MD MSc PEng George B. Rodrigues MD PhD Joanna M. Laba MD Melody Qu MD MPH Richard A. Malthaner MD MSc David A. Palma MD PhD 《Cancer》2023,129(18):2798-2807
Background
During coronavirus disease 2019 (COVID-19)–related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called SABR-BRIDGE. This study presents the preliminary surgical and pathological results.Methods
Eligible participants from four institutions (three in Canada and one in the United States) had early-stage presumed or biopsy-proven lung malignancy that would normally be surgically resected. SABR was delivered using standard institutional guidelines, with surgery >3 months following SABR with standardized pathologic assessment. Pathological complete response (pCR) was defined as absence of viable cancer. Major pathologic response (MPR) was defined as ≤10% viable tissue.Results
Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3–4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). SABR was well-tolerated, with one grade 5 toxicity (death 10 days after SABR with COVID-19) and five grade 2–3 toxicities. Following SABR, 26 patients underwent resection thus far (13 pending surgery). Median time-to-surgery was 4.5 months post-SABR (range, 2–17.5 months). Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirteen patients (50%) had pCR and 19 (73%) had MPR. Rates of pCR trended higher in patients operated on at earlier time points (75% if within 3 months, 50% if 3–6 months, and 33% if ≥6 months; p = .069). In the exploratory best-case scenario analysis, pCR rate does not exceed 82%.Conclusions
The SABR-BRIDGE approach allowed for delivery of treatment during a period of operating room closure and was well-tolerated. Even in the best-case scenario, pCR rate does not exceed 82%. 相似文献6.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
7.
Elvin S. Cheng Louiza S. Velentzis Marianne Weber Julia Steinberg Karen Canfell Xue Qin Yu 《International journal of cancer. Journal international du cancer》2023,152(12):2528-2540
There is growing, but inconsistent evidence suggesting oestrogen may play a key role in lung cancer development, especially among never-smoking women for whom lung cancer risk factors remain largely elusive. Using the China Kadoorie Biobank, a large-scale prospective cohort with 302 510 women aged 30 to 79 years recruited from 10 regions in China during 2004 to 2008, we assessed the risk of lung cancer death among self-reported never-smoking women who were cancer-free at baseline, in relation to age at menarche, age at menopause, time since menopause, prior use of oral contraceptives (OCP), number of livebirths, breastfeeding and age at first livebirth. Women were followed up to December 31, 2016 with linkage to mortality data. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression, adjusting for key confounders including several socio-demographic, environmental and lifestyle factors. Among 287 408 never-smoking women, 814 died from lung cancer with a median follow-up of 10.3 years. Women who had used OCP within 15 years prior to baseline had a significantly higher hazard of lung cancer death compared with never-users: HR = 1.85 (95% CI: 1.14-3.00) and risk increased by 6% with each additional year of use: HR = 1.06 (1.01-1.10). Among parous women, the hazard of lung cancer death increased by 13% with each single livebirth: HR = 1.13 (1.05-1.23); and among post-menopausal women, the risk increased by 2% with each year since menopause: HR = 1.02 (1.01-1.04). These results suggest that reproductive factors which were proxies for lower endogenous oestrogen level, for example, longer duration of OCP use, could play a role in lung cancer development. 相似文献
8.
9.
10.
Donor lungs cold preservation at 10 °C offers a potential logistic advantage in lung transplantation
《Cirugía espa?ola》2023,101(4):283-286
Donor lung preservation at 10 °C appears to be an innovative and promising method that may improve transplant logistics by extending the cold ischemia time with excellent outcomes. We report the case of two lung transplants from two different donors involving the use of two different preservation methods, highlighting the benefits of using 10 °C lung storage. 相似文献